Sail’s launch ends a difficult period for Laronde, a buzzy Flagship startup that brought in nearly $500 million to fund development of endless RNA-based medicines.
Laronde drew investor interest for its work creating synthetic, circular versions of the nucleic acid that could carry protein blueprints into cells. While linear strands of RNA often don’t last long, the round shape of eRNA in theory could prevent cellular enzymes from degrading the blueprints, leading to longer protein expression.
